ADVERTISEMENT
'Buy' Glenmark Pharma Maintains Motilal Oswal Citing Growth Potential, Valuation; Sees 26% Upside
With strategic initiatives implemented across business segments, Motilal Oswal expects 11%/17%/20% sales/Ebitda/PAT CAGR over FY25-27, reaching Rs 164 billion/Rs 33 billion/Rs 20 billion.
18 Apr 2025, 11:40 AM IST 
Glenmark Pharma is actively working to expand its pipeline by adding respiratory products to drive growth in the US market, says the brokerage.
(Representative image. Photo source: Envato)
Glenmark Pharma has implemented steps to reduce financial leverage through API asset monetization, optimize R&D spending on innovation assets, enhance the US generics pipeline through the development of niche products, outperform the industry in Rx, and scale the OTC business in India.
